Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol. 2017;11:117–25 Available at: https://www.karger.com/Article/FullText/447205. Accessed 1 July 2018.
Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20:130–40. Available at: http://www.jmcp.org/doi/10.18553/jmcp.2014.20.2.130. Accessed 7 June 2018.
Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urol. 2010;75:526–532.e18 Available at: http://linkinghub.elsevier.com/retrieve/pii/S0090429509023115. Accessed 1 July 2018.
•• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. J Urol. 2012;188:2455–2463. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0022534712049592. Accessed 13 Aug 2018. Current guideline for OAB treatment.
•• Apostolidis A, Averbeck MA, Sahai A, et al. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015). Neurourol Urodyn. 2017;36:882–893. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/nau.23170. Accessed 8 Apr 2018. First attempt to create a treatment algorithm for patients with OAB. It discusses AM failures, combination pharmacologic therapy, Botox vs neuromodulation, and augmentation cyoplasty—all of which is discussed in this review article.
American Urological Association. Available at: https://www.auanet.org/guidelines/incontinence-non-neurogenic-overactive-bladder-(2012-amended-2014). Accessed 30 Sept 2018.
Quirouet A, Goldman HB. Management of overactive bladder refractory to medical therapy. Current Bladder Dysfunction Reports. 2014;9:336–40 Available at: http://link.springer.com/10.1007/s11884-014-0259-2, Accessed 1 July 2018.
• Chancellor MB, Yehoshua A, Waweru C, et al. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study. Int Urol Nephrol. 2016;48:1029–1036. Available at: http://link.springer.com/10.1007/s11255-016-1277-0. Accessed 2 July 2018. Results suggest that changing between various AM medications does not improve efficacy of OAB treatment.
Komesu YM, Amundsen CL, Richter HE, et al. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. Am J Obstet Gynecol. 2018;218:111.e1–9 Available at: http://linkinghub.elsevier.com/retrieve/pii/S0002937817311882. Accessed 15 July 2018.
Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony). Eur Urol. 2015;67:577–88 Available at: http://linkinghub.elsevier.com/retrieve/pii/S0302283814001316. Accessed 2 July 2018.
Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 116:612–622. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/bju.13068. Accessed 2 July 2018.
•• Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3b study (BESIDE). Eur Urol. 2016;70:136–145. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0302283816002074. Accessed 2 July 2018. Shows the evidence to suggest the superior efficacy of combination pharmacologic therapy using an AM and beta-3 agonist compared to AM monotherapy.
Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program. Value Health. 2005;8:495–505 Available at: http://linkinghub.elsevier.com/retrieve/pii/S1098301510600435. Accessed 9 July 2018.
Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, et al. Behavior therapy to enable drug discontinuation in the treatment of urge incontinence: a randomized controlled trial. Ann Intern Med. 2008;149:161–9 Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201984/. Accessed 1 July 2018.
Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome. World J Urol. 2014;32:179–84 Available at: http://link.springer.com/10.1007/s00345-013-1112-5. Accessed 9 July 2018.
Tang H, Chen J, Wang Y, et al. Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial. Urol J. 2014;11:1800–1805
Li X, Liao L, Chen G, Wang Z, Deng H. Combination of sacral nerve and tibial nerve stimulation for treatment of bladder overactivity in pigs. Int Urol Nephrol. 2017;49:1139–45 Available at: http://link.springer.com/10.1007/s11255-017-1587-x. Accessed 15 July 2018.
• Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Int Braz J Urol. 2018;44:102–108. Available at: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382018000100102&lng=en&tlng=en. Accessed 15 July 2018. Provides evidence to suggest the superiority of combination therapy with PTNS and solifenacin vs either monotherapy alone.
Pham K, Guralnick ML, O’Connor RC. Unilateral versus bilateral stage I neuromodulator lead placement for the treatment of refractory voiding dysfunction. Neurourol Urodyn. 27:779–81 Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/nau.20577. Accessed 15 July 2018.
Marcelissen TAT, Leong RK, Serroyen J, van Kerrebroeck PEV, de Wachter SGG. The use of bilateral sacral nerve stimulation in patients with loss of unilateral treatment efficacy. J Urol. 2011;185:976–80 Available at: http://linkinghub.elsevier.com/retrieve/pii/S0022534710049669. Accessed 15 July 2018.
Scheepens WA, Bie RAD, Weil EHJ, et al. Unilateral versus bilateral sacral neuromodulation in patients with chronic voiding dysfunction. J Urol. 2002;168:2046–50.
El-Azab AS, Siegel SW. Specific tips for general controversies in sacral Neuromodulation. Curr Urol Rep. 2016;17. Available at: http://link.springer.com/10.1007/s11934-016-0640-0. Accessed 15 July 2018:79.
• Amundsen CL, Komesu YM, Chermansky C, et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxina for refractory urgency urinary incontinence: a randomized trial. Eur Urol. 2018. Results suggest no evidence of superiority between intradetrusor Botox injections and sacral neuromodulation for the treatment of OAB. Provides pros and cons of both treatment.
Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type a injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2012;61:834–9 Available at: http://linkinghub.elsevier.com/retrieve/pii/S030228381101373X. Accessed Aug 14 2018.
•• Hoag N, Plagakis S, Pillay S, et al. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxin A treatment. Neurourol Urodyn 36:1377–1381. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/nau.23117. Accessed 15 July 2018. Provides evidence that sacral neuromodulation can still provide symptomatic relief in patients who fail previous intradetrusor Botox injections.
Smits M, Oerlemans D, Macelissen T, et al. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. J Urol. 2013;190:2148–52.
Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int. 2012;109:1280–93 Available at: https://www.ncbi.nlm.nih.gov/pubmed/22117733.
Veeratterapillay R, Thorpe AC, Harding C. Augmentation cystoplasty: contemporary indications, techniques and complications. Indian J Urol. 2013;29:322–7 Available at: https://www.ncbi.nlm.nih.gov/pubmed/24235795.
Department of Health, UK. Hospital Episode Statistics. Department of Health, UK.
Shreck E, Gioia K, Lucioni A. Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA. Curr Urol Rep. 2016;17:27 Available at: https://www.ncbi.nlm.nih.gov/pubmed/26902621.
Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev. 2009: CD004202. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19370596.
de Figueiredo AA, Lucon AM, Srougi M. Bladder augmentation for the treatment of chronic tuberculous cystitis. Clinical and urodynamic evaluation of 25 patients after long term follow-up. Neurourol Urodyn. 2006;25:433–40 Available at: https://www.ncbi.nlm.nih.gov/pubmed/16791845.
Shawket TN, Muhsen J. Treatment of bilharzial-contracted bladder by ileocystoplasty or colocystoplasty. J Urol. 1967;97:285–7 Available at: https://www.ncbi.nlm.nih.gov/pubmed/6018422.
Sayegh ES, Dimmette RM. The fibrotic contracted urinary bladder associated with schistosomiasis and chronic ulceration: a clinicopathological study including treatment. J Urol. 1956;75:671–9 Available at: https://www.ncbi.nlm.nih.gov/pubmed/13307769.
Dounis A, Abel BJ, Gow JG. Cecocystoplasty for bladder augmentation. J Urol. 1980;123:164–7 Available at: https://www.ncbi.nlm.nih.gov/pubmed/7354508.
Smith RB, van Cangh P, Skinner DG, et al. Augmentation enterocystoplasty: a critical review. J Urol. 1977;118:35–9 Available at: https://www.ncbi.nlm.nih.gov/pubmed/875193.
Shirley SW, Mirelman S. Experiences with colocystoplasties, cecocystoplasties and ileocystoplasties in urologic surgery: 40 patients. J Urol. 1978;120:165–8 Available at: https://www.ncbi.nlm.nih.gov/pubmed/671623.
Hradec EA. Bladder substitution: indications and results in 114 operations. J Urol. 1965;94:406–17 Available at: https://www.ncbi.nlm.nih.gov/pubmed/5320331.
Nurse DE, Parry JR, Mundy AR. Problems in the surgical treatment of interstitial cystitis. Br J Urol. 1991;68:153–4 Available at: https://www.ncbi.nlm.nih.gov/pubmed/1822961.
van Ophoven A, Oberpenning F, Hertle L. Long-term results of trigone-preserving orthotopic substitution enterocystoplasty for interstitial cystitis. J Urol. 2002;167:603–7 Available at: https://www.ncbi.nlm.nih.gov/pubmed/11792927.
Webster GD, Maggio MI. The management of chronic interstitial cystitis by substitution cystoplasty. J Urol. 1989;141:287–91 Available at: https://www.ncbi.nlm.nih.gov/pubmed/2913346.
El-Azab AS, Moeen AM. The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxin A and augmentation cystoplasty. Arab J Urol. 2013;11:344–9 Available at: https://www.ncbi.nlm.nih.gov/pubmed/26558103.
Venn SN, Mundy AR. Long-term results of augmentation cystoplasty. Eur Urol. 1998;34(Suppl 1):40–2 Available at: https://www.ncbi.nlm.nih.gov/pubmed/9705554.
• Cheng KC, Kan CF, Chu PS, et al. Augmentation cystoplasty: Urodynamic and metabolic outcomes at 10-year follow-up. Int J Urol. 2015;22:1149–54 Available at: https://www.ncbi.nlm.nih.gov/pubmed/26391472.
Whitmore WF, Gittes RF. Reconstruction of the urinary tract by cecal and ileocecal cystoplasty: review of a 15-year experience. J Urol. 1983;129:494–8 Available at: https://www.ncbi.nlm.nih.gov/pubmed/6834531.
Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU Int. 2001;88:511–25 Available at: https://www.ncbi.nlm.nih.gov/pubmed/11678743.
Küss R, Bitker M, Camey M, et al. Indications and early and late results of intestino-cystoplasty: a review of 185 cases. J Urol. 1970;103:53–63 Available at: https://www.ncbi.nlm.nih.gov/pubmed/5415722.
George VK, Russell GL, Shutt A, et al. Clam ileocystoplasty. Br J Urol. 1991;68:487–9 Available at: https://www.ncbi.nlm.nih.gov/pubmed/1747723.
Mitchell ME, Kulb TB, Backes DJ. Intestinocystoplasty in combination with clean intermittent catheterization in the management of vesical dysfunction. J Urol. 1986;136:288–91 Available at: https://www.ncbi.nlm.nih.gov/pubmed/3723679.
Kreder KJ, Webster GD. Management of the bladder outlet in patients requiring enterocystoplasty. J Urol. 1992;147:38–41 Available at: https://www.ncbi.nlm.nih.gov/pubmed/1729548.
Khoury JM, Timmons SL, Corbel L, et al. Complications of enterocystoplasty. Urology. 1992;40:9–14 Available at: https://www.ncbi.nlm.nih.gov/pubmed/1621320.
DeFoor W, Tackett L, Minevich E, et al. Risk factors for spontaneous bladder perforation after augmentation cystoplasty. Urology. 2003;62:737–41 Available at: https://www.ncbi.nlm.nih.gov/pubmed/14550454.
Shekarriz B, Upadhyay J, Demirbilek S, et al. Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. Urology. 2000;55:123–8 Available at: https://www.ncbi.nlm.nih.gov/pubmed/10654908.
Hendren WH, Hendren RB. Bladder augmentation: experience with 129 children and young adults. J Urol. 1990;144:445–53 discussion 460. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2374218.
Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol. 2004;172:1649–51 discussion 1651–2. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15371782.
Edlund C, Peeker R, Fall M. Clam ileocystoplasty: successful treatment of severe bladder overactivity. Scand J Urol Nephrol. 2001;35:190–5 Available at: https://www.ncbi.nlm.nih.gov/pubmed/11487070.
Awad SA, Al-Zahrani HM, Gajewski JB, et al. Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. Br J Urol. 1998;81:569–73 Available at: https://www.ncbi.nlm.nih.gov/pubmed/9598629.
Beier-Holgersen R, Kirkeby LT, Nordling J. “Clam” ileocystoplasty. Scand J Urol Nephrol. 1994;28:55–8 Available at: https://www.ncbi.nlm.nih.gov/pubmed/8009194.
Apostolidis A, Popat R, Harper M, et al. Successful treatment with botulinum toxin A after failed augmentation ileocystoplasty. Nat Clin Pract Urol. 2007;4:280–4 Available at: https://www.ncbi.nlm.nih.gov/pubmed/17483813.
Rasmussen NT, Guralnick ML, O’Connor RC. Successful use of sacral neuromodulation after failed bladder augmentation. Can Urol Assoc J. 2009;3:E49–50 Available at: https://www.ncbi.nlm.nih.gov/pubmed/19829718.
Reyblat P, Ginsberg DA. Augmentation cystoplasty: what are the indications? Curr Urol Rep. 2008;9:452–8 Available at: https://www.ncbi.nlm.nih.gov/pubmed/18947509.
Ivancić V, Defoor W, Jackson E, et al. Progression of renal insufficiency in children and adolescents with neuropathic bladder is not accelerated by lower urinary tract reconstruction. J Urol. 2010;184:1768–74 Available at: https://www.ncbi.nlm.nih.gov/pubmed/20728123.
Reyblat P, Ginsberg DA. Augmentation enterocystoplasty in overactive bladder: is there still a role? Curr Urol Rep. 2010;11:432–9 Available at: https://www.ncbi.nlm.nih.gov/pubmed/20734172.
• Watanabe JH, Campbell JD, Ravelo A, et al. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010;76:835–40 Available at: https://www.ncbi.nlm.nih.gov/pubmed/20430422.